XENE Shariah Compliance

Screening Methodology: AAOIFI

lock image
UNLOCK FOR FREE

Last Updated: March 10, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Xenon Pharmaceuticals Inc (XENE)

Based on 27 analysts giving stock ratings to Xenon Pharmaceuticals Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
41
Buy
55
Hold
4
Sell
0
Strong Sell
0
Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. Stock Analysis XENE

United States Health Care Mid Cap Report:
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Read More

Xenon Pharmaceuticals Inc (XENE) Chart

Key Statistics of Xenon Pharmaceuticals Inc (XENE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$54.33$55.72

Today's Open

$55.44

Volume

966.68K

P/E Ratio (TTM)

-

52 Week Range

$26.74$63.95

Market Cap

3.09B

Avg. Volume

2.26M

Dividend Yield

-

Financial Metrics & Statements of Xenon Pharmaceuticals Inc (XENE)

Super Investors Invested in Xenon Pharmaceuticals Inc (XENE)

Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.

FAQ's for Xenon Pharmaceuticals Inc (XENE)

  • According to Musaffa’s Shariah screening methodology, Xenon Pharmaceuticals Inc (XENE) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.